Abstract: A method and composition for treating dermatological conditions and improving skin condition and helping hair to grow or thicken involves removing extracts including beneficial secretions from mesenchymal stem cells or other cells with regenerative properties to use itself or components thereof alone or with other skin or hair care reagents as a topical ointment or formula to apply to the skin or hair topically for therapeutic and cosmetic purposes.
Abstract: The invention discloses a method of coating a medical device. The method includes applying a coating composition on the medical device to form a layer on the medical device. The coating composition includes one or more of one or more biological agents and heparin dissolved in a mixture of a first solvent and a second solvent. The first solvent and the second solvent have different evaporation temperatures. Subsequently, at least a part of one of the first solvent and the second solvent present in the coating composition is evaporated to create a plurality of pores in the layer. Thereafter, one or more drugs are deposited in the plurality of pores. When the medical device is positioned and expanded at a target site, the one or more drugs are released from the plurality of pores.
Type:
Application
Filed:
January 19, 2011
Publication date:
December 13, 2012
Applicants:
Envision Scientific Private Limited, Concept Medical Research Private limited
Abstract: A process of purifying or enriching coagulation FVIII employing chromatography comprising the steps of providing a fraction containing FVIII in an aqueous solution having a high ionic strength; contacting the fraction containing FVIII with a multimodal resin; optionally washing the multimodal resin having FVIII adsorbed with an aqueous washing buffer; eluting FVIII containing fractions by an aqueous elution buffer comprising at least one amino acid which is positively charged at pH 6 to 8; and optionally collecting FVIII containing fractions in purified or enriched form.
Type:
Grant
Filed:
June 24, 2009
Date of Patent:
December 11, 2012
Assignee:
Octapharma AG
Inventors:
Carin Borgvall, Ulrika Ericsson, Gustav Gilljam, Mats Jernberg, Stefan Winge
Abstract: The invention provides an insect repellent that repels flies, gnats, mosquitoes, lice, ticks, and fleas. The insect repellent comprises an avian-based extract, in particular an extract isolated from birds of the order Psittaciformes (parrots). The invention also provides an insect repellent composition about 5 volume % to about 75 volume % of the avian-based extract and about 95 volume % to about 25 volume % of a carrier vehicle.
Abstract: The present invention relates to analyte detection test systems, including test systems for the oral detection of analytes in saliva. The present invention also provides compositions and methods for storing multiple assay tests and compositions and methods for measuring the concentration of analytes in a sample.
Type:
Grant
Filed:
October 20, 2011
Date of Patent:
December 4, 2012
Assignee:
N2itive1 Innovations
Inventors:
Anthony Toranto, Evan Singer, Brett Miller
Abstract: A process for preparing an oligosaccharide derivative from an oligosaccharide mixture, the process being characterized in that the process comprises the steps of (a) introducing a lipophilic group into oligosaccharides of the mixture to obtain a mixture of oligosaccharide derivatives, and (b) treating the oligosaccharide derivative mixture by serotonin affinity column chromatography.
Abstract: Methods of producing stem cell conditioned media to treat mammalian injuries or insults. In at least one embodiment of a method of producing a stem cell conditioned media of the present disclosure, the method comprises the steps of culturing at least one stem cell in a first cell culture medium, replacing some or all of the first cell culture medium with a second cell culture medium and further culturing the at least one stem cell in the second cell culture medium, and collecting a quantity of the second cell culture medium after a culture duration, wherein the quantity of the second cell culture medium contains a cell culture byproduct effective to treat a mammalian insult or injury. In another embodiment, the step of culturing comprises culturing the at least one stem cell in EGM2MV.
Type:
Application
Filed:
May 22, 2012
Publication date:
November 22, 2012
Inventors:
Brian H. Johnstone, Keith Leonard March, Yansheng Du
Abstract: A method for producing dry earthworm powder, by which dry earthworm powder having high-titer enzymes can be produced while removing toxic substances contained in the bodies of earthworms, is provided. The method comprises: contacting a live earthworm with a chloride(s) of at least one metal selected from the group consisting of potassium, sodium, magnesium and calcium; and subsequently contacting the live earthworm with powder of a hydroxycarboxylic acid(s) and diluting the resulting mixture with water to adjust pH to 2 to 5, followed by leaving the live earthworm to stand for 3 to 180 minutes, washing the live earthworm with water, grinding the washed live earthworm and freeze-drying the obtained ground product.
Abstract: It is intended to provide an evaluation method and a screening method capable of eliminating a substance that disturbs in vivo kinetics in an individual and capable of simply and easily searching a substance having an action of activating/suppressing an innate immune mechanism without being affected by LPS derived from bacteria, which can be contaminated during the search, as well as a drug and a food for activating/suppressing the innate immune mechanism, and methods of producing the same. The present invention provides a method of evaluating or screening the substance having the action of activating/suppressing the innate immune mechanism using a muscular contraction of an organism having the innate immune mechanism as an indicator, and methods of producing the drug and the food for activating/suppressing the innate immune mechanism.
Type:
Grant
Filed:
April 10, 2008
Date of Patent:
November 20, 2012
Assignees:
Genome Pharmaceuticals Institute Co., Ltd., The University of Tokyo, Imagine Global Care Corporation
Abstract: The invention provides glycated peptides and glycated fragments and glycated variants thereof, antibodies and aptamers which bind thereto, compositions and kits comprising the same, related conjugates, and a database comprising data indicating the concentration of glycated peptides present in diabetic and non-diabetic persons. The invention also provides a method of monitoring glycemic control, a method of treating or preventing diabetes, a method of preventing a complication of diabetes, a method of monitoring the status of diabetes, a method of determining the efficacy of a diabetes treatment, as well as methods of detecting diabetes or a predisposition thereto.
Type:
Grant
Filed:
March 6, 2007
Date of Patent:
November 13, 2012
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Abstract: Embodiments of the present invention include a surgical kit for preparation of a patch for implantation into a human body, characterized in that it comprises a package containing, on one hand, a synthetic substrate (1) and, on the other hand, means for treatment of the substrate with a solution (3) including at least one biologically active component (4, 5), adapted to integrate the biologically active component with the substrate. Embodiments of the invention include a patch for implantation into the human body, comprising a synthetic substrate (1), characterized in that at least one biologically active component (4, 5) is integrated with the substrate using the surgical kit.
Type:
Application
Filed:
June 1, 2010
Publication date:
November 8, 2012
Inventors:
Kevin L. Ohashi, Dale R. Peterson, Jamal Rushdy
Abstract: A formulation for the biological control of pests comprises a cohort of infective juvenile insect-parasitic nematodes from at least three species, wherein at least two of the species are of a first genus, and at least one of the species is from a second genus, and the species number from the first genus is greater than the species number from the second genus. The cohort of nematodes consists essentially of two species from the first genus and one species from the second genus and comprises at least one ambusher foraging species of nematode from a first genera and at least two cruiser foraging species of nematode from a different genera, or at least two ambusher foraging species of nematode from the same genera and at least one cruiser foraging species of nematode from a different genera. The first and second genus are selected from the group comprising: Steinernematidae and Heterorhapditidae.
Abstract: The present invention relates to composition containing sialic acids or precursors, and their use to improve performance-related and social parameters in mammals, particularly humans and horses. The daily dosage is preferably selected from the group consisting of 1 microgram to 100 mg/day, 100 microgram to 20 mg/day, and 200 microgram to 10 mg/day.
Abstract: A peritoneal function testing apparatus tests the peritoneal function of a dialysis patient easily and with high accuracy. Standards of four kinetic parameters (CCr, Kt/V, MTACu, and MTACc) available in a definite dialysis guideline are computed in accordance with a relational expression, and a curve showing the relation between MTACu/c and the drained fluid volume is indicated in a graph together with the PET data of the patient which has been prepared separately. Thus, the peritoneal function can be evaluated based on the relative position of the patient's data and the curve showing the standard values in the graph.
Abstract: The present disclosure provides immunoassays and kits for detection or quantification of an analyte of interest in a test sample that potentially contains endogenously produced autoantibodies reactive with the analyte.
Type:
Grant
Filed:
April 19, 2012
Date of Patent:
November 6, 2012
Assignee:
Abbott Laboratories
Inventors:
Maciej Adamczyk, Roy Jeffrey Brashear, Phillip G. Mattingly
Abstract: The invention concerns a method for the preparation of an acellular organic tissue for revitalization, in particular for the introduction of living cells, comprising a stage in which the acellular organic tissue (2; 12) is provided with a plurality of holes (4; 14) made through its surface (8; 18) and extending towards the inside of the tissue (2; 12). The holes intersect partially, thus forming holes (4; 14) partially communicating with each other. The invention also concerns the acellular organic tissue obtained with this method.
Abstract: The instant invention provides novel and effective methods of isolating alpha-1-antitrypsin from cryo-poor plasma and formulating it into therapeutic products. This invention achieves higher yields and a superior quality of alpha-1-antitrypsin. Alpha-1-antitrypsin is isolated from cryo-poor plasma, using one or more salts selected from a group comprising sodium citrate, sodium acetate, sodium gluconate, ammonium sulfate, sodium chloride, sodium sulfate and ammonium chloride in two fractionation steps, followed by diafiltration to remove those salts employed.
Type:
Grant
Filed:
December 20, 2010
Date of Patent:
October 23, 2012
Assignee:
Plasma Technologies, LLC
Inventors:
Gene Zurlo, Dennis Curtin, Allan Louderback
Abstract: A method for high spatial resolution stochastic examination of a biological sample structure labeled with a labeling substance is described. The method comprises providing a biological sample structure; choosing such a labeling substance that has molecules present in a first state and in a second state, and the first and second states differ from one another in at least one photophysical property such that there is sufficient probability that one portion of the molecules of the substance will be in the first state and another portion of the molecules will be in the second state and within which labeling substance a change of the state of the molecules can occur spontaneously between the two states in both directions; and labeling the biological sample structure with the substance.
Abstract: A method for treatment of HIV infection includes administering at least one anti-HIV drug, such as a reverse transcriptase inhibitor, to a patient in need of such treatment and administering an extract from inflammatory tissue inoculated with vaccinia virus to the patient following the administration of the at least one anti-HIV drug. The extract maintains suppressive action on HIV replication, even if the administration of the anti-HIV drug is terminated.
Abstract: The present invention relates to anti-atopic textiles, including a textile body and skin care layers formed by dyeing the textile body with a dyebath, obtained by filtering a mixture of earthworm powder and water through Korean paper. When clothes are made of the anti-atopic textiles and brought in contact with the skin, atopic dermatitis can be significantly alleviated because a moisturizing action and an anti-inflammation action are accelerated by a body composition and fluid components of earthworms included in the skin care layers and paper mulberry extract mixed from Korean paper. The anti-atopic textiles according to the present invention includes a textile body and skin care layers formed by dyeing the textile body with a dyebath which is obtained by mixing earthworm powder, obtained by pulverizing earthworms and drying the pulverized earthworms, and water and then filtering the mixture through Korean paper.
Abstract: A composition of matter comprising an agent beneficial to a non-skin keratinous substance and at least one stinging capsule and methods of use are disclosed.
Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to monitor cardiorenal syndrome using assays that detect NGAL, preferably together with assays that detect natriuretic peptides such as BNP. Such methods and compositions can provide early indications of a deterioration in cardiorenal syndrome status, including prognosis regarding mortality and worsening renal function.
Abstract: The use of extract of leeches' saliva as anti-bacterial agent for the manufacture of different compositions, such as a pharmaceutical composition, a cosmetic composition or a cleaning product.
Type:
Application
Filed:
October 15, 2010
Publication date:
October 4, 2012
Applicants:
UNIVERSITE DE LILLE 1 SCIENCES ET TECHNOLOGIES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Abstract: The invention is directed to immortalized cell compositions and compositions derived therefrom. The invention is further directed to methods of making and using such immortalized cell compositions and compositions derived therefrom. Such immortalized cell compositions include but are not limited to Immortalized Amnion-derived Multipotent Progenitor cells (herein referred to as I-AMP cells) and conditioned media derived therefrom (herein referred to as I-Amnion-derived Cellular Cytokine Solution or I-ACCS).
Abstract: A medical device, said medical device, comprises: a first component having a non-biological material; a second component having a cloned biological material, said second component being attached to said first component, wherein said first component and said second component are operatively associated in a non-living medical device for at least one of treatment, diagnosis, cure, mitigation and prevention of disease, injury, handicap or condition in a living organism. In another aspect, a method comprises: preparing a cloned biological material from a tissue or an organ; attaching said biological material to a medical device; interfacing said biological material with the non-biological material; providing treatment, diagnosis, cure, mitigation and prevention of disease, injury, handicap or condition in a living organism.
Abstract: Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder. Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, or formulated with a salve or ointment for topical applications. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium.
Type:
Application
Filed:
March 9, 2012
Publication date:
September 13, 2012
Applicant:
SkinMedica. Inc.
Inventors:
Gail K. Naughton, David L. Horwitz, Mark A. Applegate, Joan Zeltinger, Jonathan N. Mansbridge, Andreas Kern, Lee K. Landeen, Anthony Ratcliffe, R. Emmett Pinney
Abstract: The invention provides an insect repellent that repels flies, gnats, mosquitoes, lice, ticks, and fleas. The insect repellent comprises an avian-based extract, in particular an extract isolated from birds of the order Psittaciformes (parrots). The invention also provides an insect repellent composition about 5 volume % to about 75 volume % of the avian-based extract and about 95 volume % to about 25 volume % of a carrier vehicle.
Abstract: The present disclosure relates to, inter alia, compositions containing an inhibitor of human complement and use of the compositions in methods for treating or preventing complement-associated disorders. In some embodiments, the inhibitor is chronically administered to patients. In some embodiments, the inhibitor is administered to a patient in an amount and with a frequency to maintain systemic complement inhibition and prevent breakthrough. In some embodiments, the compositions contain an antibody, or antigen-binding fragment thereof, that binds to a human complement component C5 protein or a fragment of the protein such as C5a or C5b.
Type:
Application
Filed:
November 10, 2009
Publication date:
September 6, 2012
Applicant:
Alexion Pharmaceuticals, Inc.
Inventors:
Russell P. Rother, Camille Bedrosian, Stephen P. Squinto, Leonard Bell
Abstract: The present invention relates to compositions including a homeopathic aqueous substance active (HASA) and at least one hydrophilic gelling agent, the HASA comprises a homeopathic compound at a potency of 30 C or higher and an uninhibited aqueous composition. The present invention also relates to methods of preparing a hydrophilic HASA-gel matrix. The method includes combining a homeopathic compound and an uninhibited aqueous composition to produce a HASA; combining the HASA with at least one hydrophilic gelling agent; and thereafter, forming the hydrophilic HASA-gel matrix by use of at least one of a thickening agent, a crosslinking agent, or a polymerization agent.
Abstract: Extracellular matrix material is disclosed which is created by subjecting a target area to non-thermal irreversible electroporation (NTIRE) with a pulsed electrical field to kill cells in the absence of thermal damage. The dead cellular material may be removed and the remaining non-cellular matrix material may be implanted into a repair site to be treated medically or cosmetically.
Type:
Application
Filed:
September 2, 2010
Publication date:
September 6, 2012
Inventors:
Mary Phillips, Elad Maor, Boris Rubinsky, Jacob Lavee
Abstract: The present invention relates to skin care compositions, including cosmeceuticals, for topical application, and more particularly, a skin cream, comprising cell culture medium conditioned by cells grown in two-dimensional culture. Also included are methods of using such compositions and kits comprising the skin cream therein.
Abstract: Provided is a matrix for promoting survival and differentiation of cells transplanted thereon, comprising a base matrix and a cell-made matrix thereon. Methods and means for making and using same are also provided. Also provided are conditioned media, related compositions, related methods, and related packaging products.
Type:
Application
Filed:
April 5, 2012
Publication date:
August 30, 2012
Applicant:
UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY
Inventors:
Ilene Sugino, Vamsi Gullapalli, Marco Zarbin
Abstract: We describe a method of monitoring the state of a cell, the method comprising establishing, for a selected microRNA (miRNA) species secreted by the cell, a ratio of: (a) a precursor form of the miRNA species (pre-miRNA); to (b) a mature form of the miRNA species (mature miRNA); in which the pre- to mature miRNA ratio so established is indicative of the state of the cell. We also describe a method comprising the steps of: (a) providing a mesenchymal stem cell (MSC); and (b) introducing an oncogene into the mesenchymal stem cell to thereby transform it; in which the transformed mesenchymal stem cell does not secrete a gene product of the oncogene into a medium in which it is grown.
Type:
Application
Filed:
November 2, 2010
Publication date:
August 30, 2012
Applicant:
AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
Abstract: An extract for preventing or treating thrombotic disease, particularly, an extract of leech and/or earthworm with molecular weight of not more than 5800 Dalton, and processes for preparation, pharmaceutical compositions and uses thereof. The extract of the present invention has improved significantly safety without any reducing in pharmaceutical activities or the therapeutical effects as compared to existing products.
Abstract: The invention relates to a method for the diagnosis, and/or risk stratification, and/or outcome prognosis of cardiac insufficiency for NYHA I patients, wherein a determination of the proANP marker, NT-proANP marker, or fragments or partial peptides thereof is carried out parallel to a determination of BNP, proBNP, and/or NT-proBNP on patients to be examined.
Type:
Grant
Filed:
March 3, 2008
Date of Patent:
August 28, 2012
Assignee:
B.R.A.H.M.S GmbH
Inventors:
Andreas Bergmann, Nils Morgenthaler, Jana Papassotiriou, Joachim Struck, Stefan Anker
Abstract: In order to provide a biocompatible material consisting mainly of a fish scale-derived hydroxyapatite and a fish scale-derived collagen, which is adjusted so that easily digested and absorbed in a human body, the material contains a composite consisting mainly of a fish scale-derived hydroxyapatite and a fish scale-derived collagen.
Abstract: Provided are rapid and sensitive cell-free assay methods for detecting and/or measuring specific bimolecular or higher order interactions via reassembly of a split monomeric reporter protein, and methods of detecting or identifying modulators of such interactions by the effect on the signal provided by the reassembled split reporter protein. This methodology is adaptable to protein-protein, protein-peptide, protein-nucleic acid, protein-methylated or nonmethylated nucleic acid and other small or large molecule ligands and binding proteins.
Type:
Grant
Filed:
November 3, 2008
Date of Patent:
August 14, 2012
Assignee:
The Arizona Board of Regents of Behalf of the University of Arizona
Inventors:
Indraneel Ghosh, Cliff I. Stains, Jason R. Porter, Benjamin Jester, Jennifer Furman
Abstract: The invention provides methods of screening a mammalian subject to determine if the subject is at risk to develop or is suffering from, cardiovascular disease. In one embodiment, the method comprises detecting a measurable feature of at least two biomarkers in an HDL subfraction, or in a complex containing apoA-I or apoA-II isolated from a biological sample obtained from the subject, wherein the at least two biomarkers are selected from the group consisting of apoA-I, apoA-II, apoB-100, Lp(a), apoC-I, and apoC-III, combinations or portions and/or derivatives thereof, and comparing the measurable features of the at least two biomarkers from the biological sample to a reference standard, wherein a difference in the measurable features of the at least two biomarkers from the biological sample and the reference standard is indicative of the presence or risk of cardiovascular disease in the subject.
Type:
Grant
Filed:
July 8, 2009
Date of Patent:
August 14, 2012
Assignees:
Insilicos, LLC, University of Washington
Inventors:
Jay W. Heinecke, Tomas Vaisar, Bryan Prazen, Erik Nilsson
Abstract: Methods and kits for the quantitation of cellular DNA and cell numbers are provided. Passive element uptake, element-labeled DNA intercalators, and element labeled affinity reagents are used to quantify DNA and cells. The DNA and the cells are analyzed by elemental analysis, including ICP-MS. The methods and kits provide a fast and accurate analysis of cellular DNA and cell numbers.
Abstract: The present invention provides improved media for the cultivation of Clostridium histolyticum and culture supernatants for the biotechnological production of collagenase enzymes. The nutrient media according to the invention comprise one or more peptones from a non-mammalian source, preferably plant-derived peptones. The media can additionally comprise fish gelatin. The invention provides media, culture supernatants comprising Clostridium histolyticum collagenase, and methods to produce said collagenase.
Type:
Grant
Filed:
June 4, 2009
Date of Patent:
August 7, 2012
Assignee:
Roche Diagnostics Operations, Inc.
Inventors:
Bernhard Suppmann, Werner Hoelke, Artur Hoffmann, Thomas Marx, Kirsten Sonn, Johann-Peter Thalhofer
Abstract: Topical compositions containing lysate of human parthenogenetic stem cells (hpSCs), preferably within a liposomal dispersion, that reduce the visible signs of skin aging and/or cellulite.
Type:
Application
Filed:
August 2, 2011
Publication date:
August 2, 2012
Inventors:
Andrey Semechkin, Nikolay A. Turovets, Larisa S. Agapova, Ruslan A. Semechkin, Jeffrey D. Janus
Abstract: Disclosed are methods and compositions for treatment of acne or acneform conditions, particularly but not limited to, acne vulgaris with products generated from culture of stem or progenitor cells. Specifically, compositions of matter are disclosed which are useful for the treatment of acne and acne associated disease states, in particular acne vulgaris, by topical administration of products derived from stem cells or progenitor cells.
Abstract: Provided herein are, inter alia, methods for identifying a candidate compound for treating the toxic effects of compounds or molecules that bind to albumin in a subject. The methods include identifying test compounds that inhibit the binding between FcRn and albumin.
Abstract: The invention relates to the detection and quantitation of cyclodextrins and cyclodextrin derivatives in solutions comprising a protein. The invention further relates to methods of evaluating pharmaceutical preparations for the presence of residual cyclodextrins.
Type:
Grant
Filed:
December 5, 2005
Date of Patent:
July 31, 2012
Assignee:
Biogen Idec MA Inc.
Inventors:
Zoran Sosic, Rulin Qian, James Ahern, Rohin Mhatre
Abstract: The present invention relates, e.g., to a method for pre-processing a sample for mass spectral analysis, comprising cleaving proteins in the sample to peptides and immunodepleting highly abundant and/or well-ionizing and/or proteotypic peptides from the sample. Also described are methods for identifying well-ionizing peptides for use in this and other methods; analytic (diagnostic) methods using antibodies against highly ionizable peptides from a protein target of interest; and compositions kits and devices comprising antibodies of the invention.
Type:
Grant
Filed:
July 3, 2007
Date of Patent:
July 31, 2012
Assignee:
The Johns Hopkins University
Inventors:
Jennifer E. Van Eyk, David Raymond Graham, Rebekah Lynn Gundry
Abstract: Disclosed are systems and methods for developing diagnostic tests (e.g., detection, screening, monitoring, and prognostic tests) based on biomarker information from legacy clinical sample sets, for which only small sample volumes (e.g., about 0.05 to about 1.0 mL or less per sample) are typically available. For example, biomarkers (e.g., about 10, 50, 100, 150, 200, 300, or more) may be detected in the clinical samples through the use of single molecule detection and each biomarker may be detected in an assay that includes about 1 ?L or less of a legacy clinical sample.